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Possible Involvement of Exon 31 Alternative Splicing in
Phenotype and Severity of Epidermolysis Bullosa Caused by
Mutations in PLEC1
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TO THE EDITOR
Epidermolysis bullosa constitutes a group
of phenotypically diverse genodermatoses
which manifest with blistering and ero-
sions of the skin and mucous membranes
(Fine et al., 2000). Recent advances in
epidermolysis bullosa research have al-
lowed the identification of mutations in
10 different genes, which account for the
clinical heterogeneity in epidermolysis
bullosa (Pulkkinen and Uitto, 1999).
Mutations in the plectin gene
(PLEC1) are generally thought to cause
Abbreviations: EBS, epidermolysis bullosa simplex; EBS-MD, epidermolysis bullosa simplex associated
with muscular dystrophy; EBS-PA, epidermolysis bullosa simplex associated with pyloric atresia;
PTC, premature termination codon
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epidermolysis bullosa simplex (EBS)
associated with muscular dystrophy.
The majority of these cases are charac-
terized by generalized blistering and
muscular dystrophy (McLean et al.,
1996; Smith et al., 1996; Shimizu
et al., 1999). Muscle weakness is first
observed during the latter part of the
first decade of life. However, we and
other groups have recently demon-
strated that lethal EBS cases with
pyloric atresia (EBS-PA) also result from
mutations in PLEC1 (Nakamura et al.,
2005; Pfendner and Uitto, 2005b).
Seven cases of this new variant of EBS
have been reported so far (Pfendner
et al., 2005a). These patients manifest
with cutaneous blisters, aplasia cutis
congenital (severe localized absence of
skin), and pyloric atresia, which rapidly
result in the patient’s demise, often
soon after birth. This study reports two
cases with defective plectin expression
that show EBS-PA and EBS with mus-
cular dystrophy (EBS-MD). Further-
more, based on data mining from the
PLEC1 mutation database, we suggest
the possible involvement of exon 31 in
alternative splicing that may alleviate
the phenotypic severity of epidermoly-
sis bullosa cases caused by mutations in
the plectin gene.
Case 1 was a 4-month-old boy with
skin fragility from birth. There was no
other family history of skin fragility
(Figure 1a). Generalized blisters and
erosions were found over his entire
body. He was diagnosed as suffering
from pyloric atresia by routine abdomi-
nal X-ray. Case 2 was a 49-year-old
female with skin fragility from birth
(Figure 1b). Family tree showed a
history of consanguinity, although there
was no other family history of skin
fragility. She is now bedridden and
requires a respirator owing to progres-
sive muscular dystrophy. Some blisters
and erosions were observed on her
trunk and extremities.
An immunohistochemical study
using mAbs to a range of basement
membrane zone component proteins
was performed. Immunoreactivity
against plectin rod domain was mark-
edly attenuated in cases 1 and 2
(Figure 1c). Immunostaining for other
basement membrane zone proteins in-
cluding bullous pemphigoid antigens 1
and 2, the a6 and b4 integrins, laminin
5, and type VII collagens were normal
(data not shown). Direct nucleotide
sequencing of PLEC1 demonstrated that
case 1 harbored novel heterogeneous
premature termination codon (PTC)
mutations Q2466X in exon 31 and
Q2545X in exon 32, whereas case 2
harbored a novel homozygous PTC
mutation, Q1450X, in exon 31
(Figure 2a). Informed consent was
obtained from all individual subjects
in this study. The protocols were
approved by the Ethical Committee at
Hokkaido University Graduate School
of Medicine. This study was conducted
according to the Declaration of Helsinki
Principles.
Cases 1 and 2 demonstrated extra-
cutaneous involvement including PA
and MD, respectively. We believe that
the clinical features and course of case
2 were typical of EBS-MD. Although all
seven previous cases of EBS-PA showed
a severe, lethal clinical course (Pfend-
ner et al., 2005a), case 1 was much
milder than those cases and even
showed some clinical improvement
over time, so this is the first case of
EBS-PA with a relatively moderate
phenotype.
The precise pathomechanism caus-
ing the clinical differences between
EBS-MD and EBS-PA has not yet been
elucidated (Nakamura et al., 2005;
Pfendner et al., 2005a; Pfendner and
Uitto, 2005b). The PLEC1 mutation
database has accumulated almost 40
PLEC1 mutations from 22 cases of EBS-
MD and seven cases of EBS-PA (Pfend-
ner et al., 2005a, McMillan et al.,
2007). We have carefully re-examined
genotype–phenotype correlations in
EBS-MD and EBS-PA. The plectin data-
base contains many homozygous muta-
tions and we plotted only homozygous
PTC mutations in order to minimize the
effect of the expression difference
Control Case 1 Case 2
PLEC1
a b
c
Figure 1. Family trees, clinical findings and plectin expression. (a) Case 1 was a 4-month-old boy
who has exhibited skin fragility since birth. There was no family history of skin fragility. Blisters and
erosions were scattered over his whole body and oral mucous membranes were also affected. Healing
occurred without scarring and milia formation. He was diagnosed as suffering from pyloric atresia by
routine abdominal X-ray. On the fourth day after birth, pyloroplasty was performed. He suffered from
aspiration pneumonia and impairment of weight gain before the age of 6 months, but afterwards the
volume of milk taken increased and blister formation steadily lessened. No muscular and neurological
findings were observed. (b) Case 2 was a 49-year-old female with skin fragility from birth. Several blisters
and erosions were found on her trunk and extremities. Slight scar formation was seen in some areas.
Hypoplasty of her permanent dentition was seen and some nail thickening was observed. Her family tree
showed a history of consanguinity. Although mild blister formation continued, muscle symptoms had
never been found, until muscle weakness on the arms was first noted at the age of 19 years. Muscle
weakness gradually progressed, but she was able to perform routine activities. However, she could not
walk at the age of 38 years, owing to widespread muscular atrophy. She is now confined to a bed
and breathing is assisted by a respirator. (c) Direct immunofluorescence analysis using mAb HD1-121
against plectin (a kind gift from Dr Owaribe K, Nogoya University) demonstrated that immunoreactivities
were markedly attenuated in cases 1 and 2 compared with normal control. Bar¼50 mm.
1538 Journal of Investigative Dermatology (2007), Volume 127
D Sawamura et al.
Plectin Mutation
between the two PLEC1 alleles. Inter-
estingly, homozygous PTC mutations
associated with EBS and MD are
located in exon 31 except for one
(13803ins16), whereas those with EBS
with PA are located in parts of the gene
other than exon 31 (Figure 2b). Thus,
the plectin database suggested that EBS-
MD and EBS-PA were associated with
mutations in exon 31 and other than in
exon 31, respectively.
Analysis of the murine plectin gene
showed that alternative splicing re-
sulted in more than 16 plectin variants
and that tissue-specific expression of
these variants was different (Fuchs
et al., 1999; Rezniczek et al., 2003).
This leads to the possibility that PLEC1
alternative splicing affects the severity
of blistering and extracutaneous mani-
festation. Plectin comprises a central
rod domain with a a-helical coiled-coil
structure and large flanking amino-and
carboxyl-terminal globular domains
(Liu et al., 1996; Wiche, 1998). Re-
cently, one alternate splice messenger
RNA transcript which lacks exon 31
encoding the central rod domain was
identified in multiple rat tissues (Elliott
et al., 1997; Steinboeck and Kristufek
(2005)). In fact, skin fragility in patients
with PLEC1 mutations was less severe
than that observed in plectin-deficient
mice. As most of PLEC1 mutations are
located within the rod domain that was
not present in the smaller splice variant,
this variant might in part compensate
for the loss of the canonical (full length)
plectin expression in humans (Litjens
et al., 2006). To understand the expres-
sion of the rodless alternative spliced
form in various human tissues and cells,
we performed plectin domain-specific
RT-PCR, which indicated that human
cells also express the rodless isoform at
various levels (data not shown).
A combination of our mutations and
plectin expression results with the above
mutation database, suggests that exon
31 alternate splicing may restore the
PLEC1 open-reading frame in EBS-MD
patients with PTC mutations in exon 31,
and partially rescue the phenotype.
Therefore, we suggest that EBS-MD
caused by mutations in exon 31 demon-
strates a milder phenotype than EBS-PA
caused by non-exon 31 PLEC1 muta-
tions. Furthermore, the relatively mod-
erate phenotype of case 1 with non-
lethal EBS-PA might result from one
mutation associated with exon 31.
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Figure 2. PLEC1 mutations and significance of exon 31. (a) Genomic DNA was obtained from both cases
and the parents. The mutation detection strategy was performed after PCR amplification of all exons and
intron–exon borders, followed by direct automated nucleotide sequencing. The genomic DNA
nucleotides, the complementary DNA nucleotides and the amino acids of the protein were numbered
based on the previous sequence information (GenBank accession no. AH003623) (McLean et al., 1996).
Case 1 demonstrated heterozygous nonsense mutations. The maternal nonsense mutation was a C -T
transition at nucleotide c.7396 of complementary DNA in exon 31, resulting in the substitution of a
glutamine (CAG) at position 2466 with a stop codon (TAG) (Q2466X). The other paternal nonsense
mutation was also a C-T transition at nucleotide c.7633 of complementary DNA in exon 32, resulting in
the substitution of a glutamine (CAG) at position 2545 with a stop codon (TAG) (Q2545X). Case 2 showed
homozygous nonsense mutations, which was a C-T transition at nucleotide c.4348 of complementary
DNA in exon 31, resulting in the substitution of a glutamine (CAG) at position 1450 with a stop codon
(TAG) (Q1450X). (b) The plectin database shows many homozygous mutations and we plotted the
position of only homozygous PTC mutations. Interestingly, homozygous PTC mutations associated with
EBS-MD (blue circles) are located in exon 31 except for one mattation13803ins16 whereas those with
EBS-PA (red circles) are in other parts of the gene except exon 31. Q1450X (green circle) is the
present case. Amino-terminal actin binding domain, amino-terminal globular domain, rod domain and
carboxyl-terminal globular domain are shown. Positions of exons are indicated by numbers (exon no).
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A Novel GJB2 Mutation p.Asn54His in a Patient with
Palmoplantar Keratoderma, Sensorineural Hearing Loss
and Knuckle Pads
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TO THE EDITOR
Mutations in the GJB2 gene encoding
connexin26 are the major cause of
autosomal-recessive or -dominant non-
syndromic congenital sensorineural
hearing loss (SNHL) (Kelsell et al.,
1997; Kenneson et al., 2002; refer to
the connexin-deafness homepage at
http://davinci.crg.es/deafness/). In addi-
tion, connexin26 mutations have been
identified in autosomal-dominant syn-
dromic congenital SNHL with palmo-
plantar keratoderma (PPK) (Maestrini
et al., 1999; Richard et al., 2002,
2004; Brown et al., 2003; van Steensel
et al., 2004; Arita et al., 2006). We have
encountered a Japanese boy with PPK,
knuckle pads and congenital SNHL and
GJB2 mutation analysis revealed a
novel mutation p.Asn54His.
The patient was a 12-year-old Japa-
nese boy with PPK, knuckle pads on the
fingers and severe SNHL. He had a
congenital onset of profound bilateral
SNHL. At 1 year of age, he developed
PPK and knuckle pads. There was
no familial history of skin disorders
or auditory dysfunction. At age 12,
moderate PPK was seen. Knuckle
pads were apparent on all his
fingers (Figure 1a and b). Acneiform
follicular keratotic papules were seen
on his forehead and face, although
these acneiform papules might just be
acne. No mutilation (pseudoainhum)
was seen on the fingers. Nails, hair,
and teeth were normal and no
leukonychia was observed. Ophthal-
mologic examination revealed no ap-
parent abnormality.
The medical ethical committee at
Hokkaido University approved all
studies described below. The study
was conducted according to the De-
claration of Helsinki Principles. Partici-
pants or their legal guardian gave their
written informed consent. The coding
region of GJB2 (Genbank accession no.
NM 004004) was amplified from geno-
mic DNA by PCR, as described pre-
viously (Richard et al., 1998). Direct
sequencing of the patient’s PCR pro-
ducts revealed that the patient was a
heterozygote for a novel missense
mutation p.Asn54His (A to C substitu-
tion at nucleotide position 160: aspar-
agine 54 (AAC) to histidine (CAC)) in
GJB2 (Figure 1d), which was not
found in his mother. We were unable
to obtain a DNA sample from his
father. This mutation was not found in
100 normal unrelated Japanese allelesAbbreviations: PPK, palmoplantar keratoderma; SNHL, sensorineural hearing loss
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Connexin26 Mutation and Knuckle Pads
